Updated data from the ATAC trial
Monitoring bone mineral density in women on anastrozole
Other aromatase inhibitors in the adjuvant setting
Trials of ovarian suppression plus aromatase inhibitors
in premenopausal women
Breast conservation rates in the ATAC trial
Intraoperative radiation therapy
The mammography debate
ATAC trial data update: 47-month follow-up and
impact on clinical care
Anastrozole and bone loss
Prevention of bone loss with bisphosphonates
Use of other aromatase inhibitors in the adjuvant
setting
Impact of adjuvant therapy on early versus late
relapses
CALGB 9741 results and the impact on clinical care
Physician acceptance of capecitabine
Capecitabine/docetaxel combination in the adjuvant
and metastatic settings
Rationale for the trastuzumab monotherapy
trial
Results of the trastuzumab monotherapy trial in
metastatic disease
Management of patients with HER2-positive metastatic
disease
Management of patients with HER2-positive, ER-positive
metastatic disease
Vinorelbine/capecitabine (VINOCAP) for metastatic
disease
Integrating fulvestrant into clinical practice
Evolution of eligibility criteria for CALGB
9741
Trial design and rationale for dose selection
Efficacy and tolerability of dose-dense chemotherapy
Effect of hormone receptor status on impact of
dose-dense chemotherapy
Areas of future research in dose-dense therapy
Acceptance of dose density in clinical practice
